The company’s subsidiary Barr Laboratories has been given approval for clonazepam in 0.125mg, 0.25mg, 0.5mg, 1mg and 2mg measures. The company said it plans to launch the product immediately.
Klonopin (clonazepam) is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (one of the more severe forms of epilepsy), akinetic and myoclonic seizures, and, for the treatment of panic disorder, with or without agoraphobia.
Klonopin Wafers had total annual sales of approximately $18 million, based on IMS sales data for the 12 months ended June 2005.